Patents by Inventor Sutthilug Sotthivirat

Sutthilug Sotthivirat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210361663
    Abstract: The present disclosure is directed to pharmaceutical formulations comprising an amorphous inhibitor of hepatitis C vims NS5A. These pharmaceutical formulations may be prepared by roller-compaction or wet-granulation methods. The present disclosure is also directed to oral dosage forms, such as tablets, comprising such pharmaceutical formulations.
    Type: Application
    Filed: October 21, 2019
    Publication date: November 25, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sutthilug Sotthivirat, Joyce Stellabott, Walter R. Wasylaschuk
  • Publication number: 20210330660
    Abstract: The instant invention relates to liquid pharmaceutical compositions containing CGRP receptor antagonists. The CGRP receptor antagonist liquid pharmaceutical compositions of the instant invention are alcohol-free, low volume liquid pharmaceutical compositions that can be taken without water for the treatment of migraine headache.
    Type: Application
    Filed: December 7, 2020
    Publication date: October 28, 2021
    Inventors: Majid Mahjour, Leonardo R. Allain, Sutthilug Sotthivirat, Russell G. Maus, Rebecca Nofsinger, Lisa Lupton, Wei Xu, Francis Flanagan
  • Patent number: 10772888
    Abstract: Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: September 15, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Majid Mahjour, Feng Li, Decheng Ma, Sutthilug Sotthivirat
  • Publication number: 20190070161
    Abstract: The instant invention relates to liquid pharmaceutical compositions containing CGRP receptor antagonists. The CGRP receptor antagonist liquid pharmaceutical compositions of the instant invention are alcohol-free, low volume liquid pharmaceutical compositions that can be taken without water for the treatment of migraine headache.
    Type: Application
    Filed: September 10, 2018
    Publication date: March 7, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Majid Mahjour, Leonardo R. Allain, Sutthilug Sotthivirat, Russell G. Maus, Rebecca Nofsinger, Lisa Lupton, Wei Xu, Francis Flanagan
  • Publication number: 20180228826
    Abstract: The present disclosure is directed to compositions comprising blended materials comprising a substantially crystalline HCV nucleotide polymerase inhibitor; a first solid dispersion formulation, which comprises an HCV NS5a inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients; and a second solid dispersion formulation, which comprises an HCV NS3 inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 16, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: David Harris, James DiNunzio, William A Marinaro, Sutthilug Sotthivirat, Chad David Brown, Sundeep Sudish Dhareshwar, Jesse Lee Kuiper, Yung-Chi Lee, Craig Alfred McKelvey, Michael McNevin, Elise Topol Miller, Li Xiong
  • Publication number: 20180228827
    Abstract: The present disclosure is directed to compositions comprising blended materials comprising a substantially crystalline HCV nucleotide polymerase inhibitor; a solid dispersion formulation, which comprises an HCV NS5a inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof, and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 16, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: William A Marinaro, David Harris, James DiNunzio, Sutthilug Sotthivirat, Sundeep Sudish Dhareshwar, Gerard Ross Klinzing, Jesse Lee Kuiper, Yung-Chi Lee, Craig Alfred McKelvey, Michael McNevin, Li Xiong
  • Publication number: 20170231993
    Abstract: Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described.
    Type: Application
    Filed: April 10, 2017
    Publication date: August 17, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Majid Mahjour, Feng Li, Decheng Ma, Sutthilug Sotthivirat
  • Patent number: 9649311
    Abstract: Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: May 16, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Majid Mahjour, Feng Li, Decheng Ma, Sutthilug Sotthivirat
  • Publication number: 20160220552
    Abstract: The instant invention relates to liquid pharmaceutical compositions containing CGRP receptor antagonists. The CGRP receptor antagonist liquid pharmaceutical compositions of the instant invention are alcohol-free, low volume liquid pharmaceutical compositions that can be taken without water for the treatment of migraine headache.
    Type: Application
    Filed: September 11, 2014
    Publication date: August 4, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Majid Mahjour, Leonardo R. Allain, Sutthilug Sotthivirat, Russell G. Maus, Rebecca Nofsinger, Lisa Lupton, Wei Xu, Francis Flanagan
  • Publication number: 20140248345
    Abstract: This invention relates to a bilayer pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and atorvastatin, or a pharmaceutically acceptable salt thereof, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
    Type: Application
    Filed: October 20, 2012
    Publication date: September 4, 2014
    Inventors: Sutthilug Sotthivirat, Edward J. Fagan, Katherine H. Chin, Abraham B. Woldu, Charles DeLuca, Decheng Ma, Walter R. Wasylaschuk, Bhagwant Rege
  • Publication number: 20130023462
    Abstract: A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature Tg(s) of at least about 90° C.; and (C) an acetate buffer in an amount effective to provide a pH in a range of from about 5 to about 7; wherein the weight ratio of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1; the composition has a moisture content of about 0.8 wt. % or less; and the composition has a glass transition temperature Tg(c) of at least about 55° C. The lyophilized composition has good storage stability at temperatures up to and including room temperature. The composition can be reconstituted for use in preventing or treating fungal infections.
    Type: Application
    Filed: September 27, 2012
    Publication date: January 24, 2013
    Inventors: Sachin Mittal, Hossain Jahansouz, Sutthilug Sotthivirat
  • Publication number: 20120213851
    Abstract: Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described.
    Type: Application
    Filed: October 21, 2010
    Publication date: August 23, 2012
    Inventors: Majid Mahjour, Feng Li, Decheng Ma, Sutthilug Sotthivirat
  • Publication number: 20120059011
    Abstract: This invention relates to pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and pioglitazone, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.
    Type: Application
    Filed: June 4, 2010
    Publication date: March 8, 2012
    Inventors: Nicholas Birringer, Christopher T. John, Adam Procopio, Bhagwant Rege, Lawrence A. Rosen, Sutthilug Sotthivirat, Wei Xu
  • Patent number: 8003672
    Abstract: Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabiniod inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: August 23, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig McKelvey, Sarah Geers, Justin Moser, Bhagwant Rege, Dina Zhang, Sutthilug Sotthivirat
  • Publication number: 20090264476
    Abstract: Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabinoid inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.
    Type: Application
    Filed: April 17, 2009
    Publication date: October 22, 2009
    Inventors: Craig McKelvey, Sarah Geers, Justin Moser, Bhagwant Rege, Dina Zhang, Sutthilug Sotthivirat
  • Publication number: 20090264436
    Abstract: Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabiniod inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.
    Type: Application
    Filed: April 17, 2009
    Publication date: October 22, 2009
    Inventors: Craig McKelvey, Sarah Geers, Justin Moser, Bhagwant Rege, Dina Zhang, Sutthilug Sotthivirat